KYKevin C. Yim

Kevin C. Yim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kevin C. Yim has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Alexander Bukreyev

    Department of Pathology, University of Texas Medical Branch, Galveston, USA

    1 shared publication
  • Arin Ghasparian

    Virometix AG, Schlieren, Switzerland

    1 shared publication
  • Armando Zuniga

    Virometix AG, Wagisstrasse 14, CH-8952 Schlieren, Switzerland

    1 shared publication
  • Gregory A. Prince

    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases,1 Molecular Immunogenetics and Vaccine Research Section, Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland,2 Virion Systems, Inc., Rockville, Maryland3

    1 shared publication
  • Hugh A. Sampson

    DBV Technologies, 12 East 49th Street Tower 49, Suite 4001, New York, NY 10017, USA

    1 shared publication
  • Igor M. Belyakov

    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases,1 Molecular Immunogenetics and Vaccine Research Section, Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland,2 Virion Systems, Inc., Rockville, Maryland3

    1 shared publication

Latest Publications

  • Open Access

    Epicutaneous immunization using synthetic virus-like particles efficiently boosts protective immunity to respiratory syncytial virus

    by Pierre-Louis Hervé, Véronique Dhelft, Armando Zuniga, Arin Ghasparian, Oliver Rassek, Kevin C. Yim, Nathalie Donne, Paul-Henri Lambert, Pierre-Henri Benhamou, Hugh A. Sampson, et al.


  • Open Access

    Expression of Interleukin-4 by Recombinant Respiratory Syncytial Virus Is Associated with Accelerated Inflammation and a Nonfunctional Cytotoxic T-Lymphocyte Response following Primary Infection but Not following Challenge with Wild-Type Virus

    by Alexander Bukreyev, Igor M. Belyakov, Gregory A. Prince, Kevin C. Yim, Katie K. Harris, Jay A. Berzofsky, Peter L. Collins

    The outcome of a viral infection or of immunization with a vaccine can be influenced by the local cytokine environment. In studies of experimental vaccines against respiratory syncytial virus (RSV), an increased stimulation of Th2 (T helper 2) lymphocytes was associated with increased immunopathology upon subsequent RSV infection. For this study, we investigated the effect of increased local expression of the Th2 cytokine interleukin-4 (IL-4) from the genome of a recombinant RSV following primary infection and after a challenge with wild-type (wt) RSV. Mice infected with RSV/IL-4 exhibited an accelerated pulmonary inflammatory response compared to those infected with wt RSV, although the wt RSV group caught up by day 8. In the first few days postinfection, RSV/IL-4 was associated with a small but significant acceleration in the expansion of pulmonary T lymphocytes specific for an RSV CD8+cytotoxic T-lymphocyte (CTL) epitope presented as a major histocompatibility complex class I tetramer. However, by day 7 the response of tetramer-positive T lymphocytes in the wt RSV group caught up and exceeded that of the RSV/IL-4 group. At all times, the CTL response of the RSV/IL-4 group was deficient in the production of gamma interferon and was nonfunctional for in vitro cell killing. The accelerated inflammatory response coincided with an accelerated accumulation and activation of pulmonary dendritic cells early in infection, but thereafter the dendritic cells were deficient in the expression of B7-1, which governs the acquisition of cytolytic activity by CTL. Following a challenge with wt RSV, there was an increase in Th2 cytokines in the animals that had previously been infected with RSV/IL-4 compared to those previously infected with wt RSV, but the CD8+CTL response and the amount of pulmonary inflammation were not significantly different. Thus, a strong Th2 environment during primary pulmonary immunization with live RSV resulted in early inflammation and a largely nonfunctional primary CTL response but had a minimal effect on the secondary response.